Michael Overman
迈克尔·奥弗曼
MD
Professor, Department of Gastrointestinal Medical Oncology消化系统肿瘤内科学教授
👥Biography 个人简介
Dr. Michael Overman is a GI oncologist at MD Anderson who led pivotal trials establishing checkpoint inhibitors as standard of care for MSI-H/dMMR colorectal cancer. His work with nivolumab and ipilimumab in this subtype defined a new era of immunotherapy-responsive colorectal cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Immunotherapy in MSI-H Colorectal Cancer
Led the CheckMate 142 trial showing nivolumab plus ipilimumab produced durable responses in MSI-H/dMMR colorectal cancer, enabling FDA approval.
Biomarker-Driven CRC Treatment
Advanced molecular subtyping of colorectal cancer to identify immunotherapy-responsive populations, guiding precision treatment selection.
Representative Works 代表性著作
Nivolumab in patients with metastatic DNA mismatch repair–deficient or microsatellite instability–high colorectal cancer (CheckMate 142)
Lancet Oncology (2017)
Seminal trial demonstrating durable responses with nivolumab in MSI-H colorectal cancer, leading to accelerated FDA approval.
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer
Journal of Clinical Oncology (2018)
Updated CheckMate 142 data confirming long-term benefit of dual checkpoint blockade in MSI-H colorectal cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 迈克尔·奥弗曼 的研究动态
Follow Michael Overman's research updates
留下邮箱，当我们发布与 Michael Overman（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment